Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia: Correlations with CSF HVA

Alien R. Doran, David R. Rubinow, Owen M. Wolkowitz, Alec Roy, Alan Breier, David Pickar

Research output: Contribution to journalArticle

20 Scopus citations


CSF somatostatin and homovanillic acid (HVA) were measured in 14 schizophrenic patients while they were drug-free and during chronic fluphenazine treatment. CSF somatostatin was significantly reduced and CSF HVA was significantly elevated (p < 0.002) during fluphenazine treatment. There was a trend toward correlation between CSF somatostatin and CSF HVA in the 14 schizophrenic patients when drug-free (r = 0.49, p < 0.07) and fluphenazine-treated (r = 0.47, p < 0.08). When examined in a larger group (n = 46) of drug-free schizophrenics, this relationship was highly significant (r = 0.59, p < 0.001). These clinical data are consistent with preclinical evidence indicating a functional interaction between CMS somatostatin and dopamine systems.

Original languageEnglish (US)
Pages (from-to)431-439
Number of pages9
JournalBiological psychiatry
Issue number4
StatePublished - Feb 15 1989


ASJC Scopus subject areas

  • Biological Psychiatry

Cite this